ArticleCureus2025
Anti-thyroid Peroxidase Antibody Positivity and Chronic Hyperglycemia as Key Risk Factors for Peripheral Artery Disease in Type 2 Diabetes: A Retrospective Cohort Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnti-thyroid peroxidase antibody (TPOAb) affects metabolic and thyroid function parameters, which may worsen macrovascular complications. This study aims to find the association between chronic hyperglycemia, thyroid autoantibody, and peripheral artery disease (PAD) in type 2 diabetes mellitus (T2DM) patients, as well as examine important clinical demographic and metabolic variables.
methodsThis is a retrospective cohort study. Data from 2017-2023 of T2DM patients were collected. A total of 300 patients were included. Further, the T2DM patients are subdivided by TPOAb values. TPOAb categorized (0-60 IU/mL) as negative; TPOAb titer (>60 IU/mL) as positive. To analyze the data, IBM SPSS Statistics for Windows, Version 29.0.2.0 (Released 2022; IBM Corp., Armonk, New York, United States) was utilized. For continuous variables, the independent samples t-test for normally distributed data and the Mann-Whitney U test for non-normally distributed data were performed. The chi-square test was used to assess the association between categorical variables. The risk of PAD was assessed using univariate and multivariate binary logistic regression analysis. P<0.05 was set as statistically significant.
resultsThe prevalence of PAD was significantly higher in the TPOAb-positive group (38.5%) compared to the TPOAb-negative group (21.6%, p = 0.004). Multivariate analysis finds that poorly controlled HbA1c had an increased risk of PAD compared to well-controlled individuals (OR: 2.14, p = 0.046). Those who had diabetes for >10-15 years showed the highest risk (OR: 3.67, P = 0.002), followed by those with diabetes for more than 15 years (OR: 2.22, P = 0.038). Similarly, TPOAb positivity was independently correlated with increased odds of PAD (OR: 2.48, P = 0.003) and therefore potentially heightened the risk of macrovascular complications in association with thyroid autoimmunity.
conclusionTPOAb positivity is associated with an increased risk of PAD. In addition, poor glycemic control and longer diabetes duration were associated with PAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.